개방각 녹내장 치료제 시장 - 세계 예측(2026-2032년)

The Open-Angle Glaucoma Therapeutics Market is projected to grow by USD 18.73 billion at a CAGR of 9.06% by 2032.

Open-angle glaucoma therapeutics are central to preventing irreversible vision loss in one of the world's leading causes of blindness. Open-angle glaucoma is typically chronic, progressive, and asymptomatic in early stages, making long-term intraocular pressure control, treatment adherence, and early intervention critical priorities for ophthalmology care. Current therapeutic strategies include prostaglandin analogs, beta-blockers, alpha agonists, carbonic anhydrase inhibitors, rho kinase inhibitors, fixed-dose combinations, selective laser trabeculoplasty, and surgical adjuncts that support pressure reduction when pharmacologic control is insufficient.

The clinical landscape is shaped by the need to delay optic nerve damage while reducing treatment burden. Preservative-free formulations, sustained-release drug delivery systems, neuroprotection research, minimally invasive glaucoma surgery adjunctive therapy, and digital adherence tools are increasingly influencing therapeutic decision-making. Payers, providers, and regulators are also emphasizing real-world outcomes, patient persistence, safety in elderly populations, and equitable access to ophthalmic care. As glaucoma prevalence rises with population aging, the sector is moving toward more personalized, durable, and patient-centric treatment models.

Transformative Shifts in the Therapeutics Landscape

The open-angle glaucoma therapeutics landscape is undergoing a structural shift from symptom-managed chronic treatment toward integrated disease control. Historically, topical eye drops formed the foundation of therapy, but adherence challenges remain well documented because patients often require lifelong, daily dosing despite minimal symptoms. This has accelerated interest in fixed-dose combinations, once-daily regimens, preservative-free ophthalmic products, and sustained-release technologies designed to simplify therapy while limiting ocular surface toxicity.

Clinical practice is also becoming more algorithm-driven, with ophthalmologists increasingly combining pharmacologic therapy, selective laser trabeculoplasty, and minimally invasive procedures earlier in the care pathway for selected patients. Evidence supporting laser trabeculoplasty as an effective first-line or adjunctive intervention has encouraged broader adoption in health systems seeking durable intraocular pressure reduction and reduced dependence on topical medications. At the same time, the therapeutic pipeline is expanding beyond conventional pressure-lowering mechanisms to include trabecular outflow modulation, nitric oxide donation, rho kinase inhibition, and investigative neuroprotective approaches.

Another major transformation is the growing role of patient stratification. Disease severity, target intraocular pressure, corneal thickness, optic nerve status, comorbidities, ocular surface disease, medication tolerance, and socioeconomic access now influence therapy selection more explicitly. This is pushing the industry toward differentiated formulations, evidence-based sequencing, and adherence-enabling care models that address both clinical efficacy and patient behavior.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence open-angle glaucoma therapeutics by improving diagnosis, risk stratification, monitoring, and treatment personalization. AI-enabled analysis of optical coherence tomography, fundus imaging, visual field testing, and electronic health records can support earlier identification of structural and functional progression. Earlier detection is clinically significant because therapeutic intervention is most effective when optic nerve damage is limited and target pressure can be established before advanced vision loss occurs.

AI also has practical implications for treatment optimization. Predictive models may help clinicians identify patients at higher risk of rapid progression, poor adherence, or insufficient intraocular pressure response, enabling more proactive escalation to combination therapy, laser treatment, sustained-release options, or surgical referral. In clinical research, AI can enhance patient selection, endpoint analysis, imaging interpretation, and real-world evidence generation, supporting more precise evaluation of therapeutic durability and safety.

The cumulative impact of AI will depend on validation, explainability, bias reduction, cybersecurity, and integration into ophthalmology workflows. Datasets must reflect diverse populations because glaucoma risk and treatment access differ by ancestry, age, geography, and health system capacity. When responsibly deployed, AI can strengthen open-angle glaucoma therapeutics by linking early detection, individualized treatment pathways, and longitudinal disease surveillance into a more efficient care continuum.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East & Africa

Asia-Pacific is a critical region for open-angle glaucoma therapeutics due to large aging populations, increasing screening activity, and a growing burden of chronic eye disease. Japan, China, India, South Korea, and Australia are seeing greater demand for long-term intraocular pressure management, supported by expanding ophthalmology infrastructure and rising awareness of preventable blindness. However, access remains uneven across urban and rural settings, making affordability, generic availability, scalable screening, and teleophthalmology central to therapeutic uptake.

North America demonstrates advanced adoption of innovative glaucoma therapies, driven by established ophthalmology networks, widespread diagnostic imaging, clinical guideline utilization, and access to laser and surgical adjuncts. The United States and Canada emphasize early diagnosis, medication adherence, preservative-free formulations, and integration of real-world evidence into care quality programs. Latin America continues to improve glaucoma care through specialist expansion and public health awareness, although economic disparities, out-of-pocket costs, and delayed diagnosis remain important barriers to sustained treatment.

Europe benefits from structured healthcare systems, established reimbursement pathways, and strong adherence to evidence-based glaucoma management. Countries across Western Europe show high utilization of diagnostic technologies and combination treatment strategies, while Eastern Europe continues to strengthen access to modern pharmacologic and procedural care. The Middle East is investing in tertiary eye care, digital health infrastructure, and specialist services, particularly in high-income Gulf states, while broader regional access varies by national healthcare capacity. Africa faces significant gaps in early diagnosis and continuous treatment access, yet the region has high clinical relevance because glaucoma-related blindness is often detected late; community screening, affordable medicines, task-sharing, and training of eye care professionals are key priorities.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7 & NATO

ASEAN countries are increasingly prioritizing preventable blindness and chronic eye disease management as healthcare systems expand specialist capacity and screening programs. Demand for open-angle glaucoma therapeutics in ASEAN is influenced by demographic aging, uneven access between metropolitan and rural areas, and the need for affordable pressure-lowering therapies. Public-private initiatives, teleophthalmology, community eye health programs, and pharmacy access can support earlier treatment continuity across diverse health systems.

The GCC shows strong potential for advanced glaucoma care due to investment in specialist hospitals, digital health systems, and tertiary ophthalmology services. High rates of metabolic disease, aging populations, and health system modernization reinforce demand for comprehensive eye care, including pharmacologic therapy, laser trabeculoplasty, and surgical adjuncts. The European Union provides one of the most structured environments for evidence-based glaucoma therapeutics, with regulatory emphasis on safety, quality, pharmacovigilance, and equitable access across member states, although reimbursement rules, formulary decisions, and prescribing practices vary by country.

BRICS countries represent a diverse set of therapeutic environments, combining large patient populations, growing domestic pharmaceutical capacity, and significant access challenges. China, India, Brazil, Russia, and South Africa differ in screening infrastructure and reimbursement models, but all face pressure to expand early diagnosis and long-term treatment adherence. G7 countries tend to lead in advanced diagnostics, clinical trial activity, regulatory rigor, and adoption of innovative delivery systems, while NATO member states overlap significantly with high-income healthcare systems in North America and Europe, where ophthalmology care is increasingly guided by integrated diagnostics, standardized clinical pathways, and quality-driven outcomes.

Key Country Insights: United States, Canada, Mexico, Brazil, UK, Germany, France, Russia, Italy, Spain, China, India, Japan, Australia & South Korea

The United States remains a highly developed environment for open-angle glaucoma therapeutics, supported by advanced diagnostics, specialist availability, clinical guideline adoption, and broad use of pharmacologic, laser, and surgical adjunctive options. Canada similarly emphasizes evidence-based treatment and access through provincial healthcare systems, although geographic distribution of specialist services can affect timely care. Mexico is advancing glaucoma awareness and ophthalmology access, yet affordability and delayed diagnosis remain relevant challenges. Brazil has a large ophthalmic care need, with public and private systems supporting treatment access while regional disparities influence continuity of care.

In Europe, the United Kingdom applies structured clinical guidance and referral pathways that support standardized glaucoma management. Germany benefits from strong diagnostic infrastructure and specialist care, while France emphasizes regulated access to ophthalmic medicines and chronic disease management. Italy and Spain maintain broad ophthalmology capabilities but face capacity pressures from aging populations. Russia has established ophthalmology expertise in major urban centers, though access consistency can vary across regions.

China faces a substantial glaucoma care burden due to population size and aging, with increasing investment in diagnostic capacity, specialist services, and domestic therapeutic availability. India has a major unmet need because many cases are detected late, making affordable medicines, screening expansion, and adherence support especially important. Japan has a mature glaucoma therapeutics environment with high awareness of aging-related eye disease and strong diagnostic adoption. Australia benefits from organized eye care services and public health attention to preventable blindness, particularly in remote and Indigenous communities. South Korea combines advanced healthcare infrastructure, high technology adoption, and specialist-led glaucoma care, supporting use of modern diagnostics and individualized treatment strategies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies and delivery models that improve long-term adherence, reduce dosing complexity, and address ocular surface tolerability. Preservative-free products, fixed-dose combinations, sustained-release platforms, and therapies with differentiated mechanisms should be aligned with real-world evidence demonstrating durability, safety, persistence, and patient-reported benefits.

Stakeholders should also invest in integrated glaucoma care pathways that connect screening, diagnosis, treatment initiation, monitoring, and escalation. Partnerships with eye care providers, pharmacies, digital health platforms, academic centers, and public health programs can improve early identification and continuity of therapy. In lower-access regions, affordability strategies, local manufacturing partnerships, professional training, and simplified treatment protocols can expand reach without compromising quality.

AI-enabled tools should be pursued responsibly, with clinically validated algorithms, diverse datasets, explainable outputs, and workflow integration that supports rather than replaces ophthalmologist judgment. Regulatory and market access strategies should emphasize patient-centered outcomes, adherence benefits, reduced progression risk, and health system efficiency. Competitive differentiation will increasingly depend on demonstrating not only intraocular pressure reduction but also convenience, tolerability, durability, equitable access, and measurable value in everyday clinical practice.

Research Methodology

The research methodology for evaluating open-angle glaucoma therapeutics combines secondary research, primary validation, clinical evidence review, and structured analytical interpretation. Secondary research includes peer-reviewed ophthalmology literature, clinical guidelines, regulatory documents, public health sources, pharmacovigilance references, disease burden studies, and real-world evidence publications. These sources support assessment of treatment patterns, therapeutic classes, care pathways, technology adoption, and access considerations.

Primary research typically includes interviews and discussions with ophthalmologists, optometrists, clinical researchers, hospital procurement stakeholders, pharmacists, payers, and policy experts. These inputs help validate treatment adoption trends, adherence barriers, prescribing preferences, reimbursement dynamics, and regional access conditions. Clinical evidence is evaluated across efficacy, safety, durability, dosing burden, ocular tolerability, contraindications, and applicability to different patient populations.

Analytical triangulation is applied to compare source consistency, identify regional variations, and distinguish established evidence from emerging hypotheses. Particular attention is given to avoiding unsupported assumptions, especially in areas such as therapeutic adoption, access barriers, AI integration, and procedural adjunct use. The methodology emphasizes verified, data-backed interpretation without relying on market sizing, market share, or forecasting claims.

Conclusion

Open-angle glaucoma therapeutics are evolving toward more durable, individualized, and adherence-focused care. While intraocular pressure reduction remains the core therapeutic objective, the broader treatment landscape now includes improved formulations, fixed-dose combinations, sustained-release approaches, laser therapy integration, minimally invasive procedural adjuncts, and AI-supported disease monitoring. These developments reflect the clinical reality that long-term success depends on early detection, sustained treatment persistence, and timely escalation when progression risk is high.

Regional and country-level differences in healthcare infrastructure, affordability, specialist availability, and screening capacity continue to shape therapeutic access. High-income markets are advancing toward precision monitoring and innovative delivery systems, while emerging and underserved regions require scalable solutions that improve diagnosis and continuity of care. Industry participants that focus on patient-centered outcomes, real-world durability, equitable access, and validated digital integration will be best positioned to support the next phase of glaucoma care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Open-Angle Glaucoma Therapeutics Market, by Drug Class

• 7.1. Introduction
• 7.2. Alpha Agonists
• 7.3. Beta Blockers
  • 7.3.1. Betaxolol
  • 7.3.2. Metipranolol
  • 7.3.3. Timolol
• 7.4. Carbonic Anhydrase Inhibitors
• 7.5. Fixed Dose Combinations
• 7.6. Prostaglandin Analogues
  • 7.6.1. Bimatoprost
  • 7.6.2. Latanoprost
  • 7.6.3. Tafluprost
  • 7.6.4. Travoprost
• 7.7. Rho Kinase Inhibitors
• 7.8. Cholinergic Agents

8. Open-Angle Glaucoma Therapeutics Market, by Therapy Type

• 8.1. Introduction
• 8.2. Combination Therapy
  • 8.2.1. Beta Blocker & Prostaglandin
  • 8.2.2. Carbonic Anhydrase Inhibitor & Beta Blocker
• 8.3. Monotherapy

9. Open-Angle Glaucoma Therapeutics Market, by Route Of Administration

• 9.1. Introduction
• 9.2. Intravenous
• 9.3. Oral
• 9.4. Topical

10. Open-Angle Glaucoma Therapeutics Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies
• 10.5. Specialty Pharmacies
• 10.6. Mail-Order Pharmacies

11. Open-Angle Glaucoma Therapeutics Market, by End User

• 11.1. Introduction
• 11.2. Hospitals
  • 11.2.1. Tertiary Care Hospitals
  • 11.2.2. Community Hospitals
• 11.3. Ambulatory Surgical Centers
• 11.4. Ophthalmology Specialty Clinics
• 11.5. Optometry Practices
• 11.6. Academic & Research Centers

12. Open-Angle Glaucoma Therapeutics Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Open-Angle Glaucoma Therapeutics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Open-Angle Glaucoma Therapeutics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbisko Therapeutics Co., Ltd.
• 16.2. AbbVie Inc.
• 16.3. Aerie Pharmaceuticals, Inc.
• 16.4. Ajanta Pharma Limited
• 16.5. Akorn Operating Company LLC
• 16.6. Alcon Inc.
• 16.7. Amorphex Therapeutics Holdings, Inc.
• 16.8. Apotex Inc.
• 16.9. Astellas Pharma Inc.
• 16.10. Bausch Health Companies Inc.
• 16.11. Cipla Limited
• 16.12. EyePoint Pharmaceuticals, Inc.
• 16.13. Genentech, Inc.
• 16.14. Glaukos Corporation
• 16.15. Harrow, Inc.
• 16.16. iVeena Holdings, Inc.
• 16.17. Johnson & Johnson Services, Inc.
• 16.18. Kowa Company, Ltd.
• 16.19. Lupin Limited
• 16.20. Merck & Co., Inc.
• 16.21. Nicox S.A.
• 16.22. Novartis AG
• 16.23. Ocular Therapeutix, Inc.
• 16.24. Ocuphire Pharma, Inc.
• 16.25. Pfizer Inc.
• 16.26. Santen Pharmaceutical Co., Ltd.
• 16.27. Senju Pharmaceutical Co., Ltd.
• 16.28. Sun Pharmaceutical Industries Ltd.
• 16.29. Teva Pharmaceutical Industries Ltd.
• 16.30. Viatris Inc.